142 related articles for article (PubMed ID: 10051059)
21. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants.
Gardiner SJ; Kristensen JH; Begg EJ; Hackett LP; Wilson DA; Ilett KF; Kohan R; Rampono J
Am J Psychiatry; 2003 Aug; 160(8):1428-31. PubMed ID: 12900304
[TBL] [Abstract][Full Text] [Related]
22. Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring.
Olesen OV; Poulsen B; Linnet K
Ther Drug Monit; 2001 Feb; 23(1):51-5. PubMed ID: 11206044
[TBL] [Abstract][Full Text] [Related]
23. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients.
Bergemann N; Frick A; Parzer P; Kopitz J
Pharmacopsychiatry; 2004 Mar; 37(2):63-8. PubMed ID: 15048613
[TBL] [Abstract][Full Text] [Related]
24. Olanzapine concentrations in clinical serum and postmortem blood specimens--when does therapeutic become toxic?
Robertson MD; McMullin MM
J Forensic Sci; 2000 Mar; 45(2):418-21. PubMed ID: 10782964
[TBL] [Abstract][Full Text] [Related]
25. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.
Melkersson KI; Hulting AL; Brismar KE
J Clin Psychiatry; 2000 Oct; 61(10):742-9. PubMed ID: 11078035
[TBL] [Abstract][Full Text] [Related]
26. Integration of olanzapine determinations in a HPLC-diode array detection system for routine psychotropic drug monitoring.
Llorca PM; Coudore F; Corpelet C; Buyens A; Hoareau M; Eschalier A
Clin Chem; 2001 Sep; 47(9):1719-21. PubMed ID: 11514415
[No Abstract] [Full Text] [Related]
27. High-dose olanzapine and prolactin levels.
Karagianis JL; Baksh A
J Clin Psychiatry; 2003 Oct; 64(10):1192-4. PubMed ID: 14658967
[TBL] [Abstract][Full Text] [Related]
28. Olanzapine overdose with serum concentrations.
Cohen LG; Fatalo A; Thompson BT; Di Centes Bergeron G; Flood JG; Poupolo PR
Ann Emerg Med; 1999 Aug; 34(2):275-8. PubMed ID: 10424935
[TBL] [Abstract][Full Text] [Related]
29. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers.
Markowitz JS; Devane CL; Liston HL; Boulton DW; Risch SC
Clin Pharmacol Ther; 2002 Jan; 71(1):30-8. PubMed ID: 11823755
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy With Olanzapine in Daily Clinical Practice.
Fekete S; Wewetzer C; Mehler-Wex C; Holtkamp K; Burger R; Reichert S; Taurines R; Romanos M; Gerlach M; Egberts K
Ther Drug Monit; 2017 Jun; 39(3):273-281. PubMed ID: 28383317
[TBL] [Abstract][Full Text] [Related]
31. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
Alfaro CL; Wudarsky M; Nicolson R; Gochman P; Sporn A; Lenane M; Rapoport JL
J Child Adolesc Psychopharmacol; 2002; 12(2):83-91. PubMed ID: 12188977
[TBL] [Abstract][Full Text] [Related]
32. Applicability of an assay for routine monitoring of highly variable concentrations of olanzapine based on HPLC with mass spectrometric detection.
Gervasini G; Vizcaíno S; Herráiz AG; Benítez J; Carrillo JA
Clin Chem; 2003 Dec; 49(12):2088-91. PubMed ID: 14633885
[No Abstract] [Full Text] [Related]
33. Olanzapine. Pharmacokinetic and pharmacodynamic profile.
Callaghan JT; Bergstrom RF; Ptak LR; Beasley CM
Clin Pharmacokinet; 1999 Sep; 37(3):177-93. PubMed ID: 10511917
[TBL] [Abstract][Full Text] [Related]
34. Differential olanzapine plasma concentrations by sex in a fixed-dose study.
Kelly DL; Conley RR; Tamminga CA
Schizophr Res; 1999 Nov; 40(2):101-4. PubMed ID: 10593449
[TBL] [Abstract][Full Text] [Related]
35. Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol.
Linnet K; Wiborg O
Ther Drug Monit; 1996 Dec; 18(6):629-34. PubMed ID: 8946657
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine: interaction study with imipramine.
Callaghan JT; Cerimele BJ; Kassahun KJ; Nyhart EH; Hoyes-Beehler PJ; Kondraske GV
J Clin Pharmacol; 1997 Oct; 37(10):971-8. PubMed ID: 9505989
[TBL] [Abstract][Full Text] [Related]
37. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.
Nyberg S; Farde L; Halldin C
Neuropsychopharmacology; 1997 Jan; 16(1):1-7. PubMed ID: 8981383
[TBL] [Abstract][Full Text] [Related]
38. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
[TBL] [Abstract][Full Text] [Related]
39. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.
Spina E; D'Arrigo C; Santoro V; Muscatello MR; Pandolfo G; Zoccali R; Diaz FJ; de Leon J
Ther Drug Monit; 2009 Dec; 31(6):758-63. PubMed ID: 19865002
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections.
Tveito M; Smith RL; Høiseth G; Molden E
J Clin Psychopharmacol; 2019; 39(6):561-566. PubMed ID: 31688390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
